Liu, Chang http://orcid.org/0009-0008-8169-4572
Das, Raksha
Dijokaite-Guraliuc, Aiste http://orcid.org/0000-0002-4850-9709
Zhou, Daming http://orcid.org/0000-0002-7188-5243
Mentzer, Alexander J. http://orcid.org/0000-0002-4502-2209
Supasa, Piyada
Selvaraj, Muneeswaran
Duyvesteyn, Helen M. E.
Ritter, Thomas G. http://orcid.org/0000-0002-3153-342X
Temperton, Nigel http://orcid.org/0000-0002-7978-3815
Klenerman, Paul
Dunachie, Susanna J. http://orcid.org/0000-0001-5665-6293
Paterson, Neil G. http://orcid.org/0000-0003-4292-6971
Williams, Mark A. http://orcid.org/0000-0001-9031-9725
Hall, David R. http://orcid.org/0000-0002-5333-6136
Fry, Elizabeth E. http://orcid.org/0000-0001-9754-5303
Mongkolsapaya, Juthathip http://orcid.org/0000-0003-3416-9480
Ren, Jingshan http://orcid.org/0000-0003-4015-1404
Stuart, David I. http://orcid.org/0000-0002-3426-4210
Screaton, Gavin R. http://orcid.org/0000-0002-3549-4309
Funding for this research was provided by:
Chinese Academy of Medical Sciences (2018-I2M-2-002)
RCUK | Medical Research Council (MR/N00065X/1)
Article History
Received: 30 November 2023
Accepted: 29 March 2024
First Online: 16 April 2024
Competing interests
: G.R.S. sits on the GSK Vaccines Scientific Advisory Board, consults for AstraZeneca and is a founder member of RQ Biotechnology. D.I.S. consults for AstraZeneca. Oxford University holds intellectual property related to SARS-CoV-2 mAbs discovered in G.R.S.’s laboratory. S.J.D. is a Scientific Advisor to the Scottish Parliament on COVID-19. The remaining authors declare no competing interests.